Evidence map›Paper›PMID 38051998›Full record

ArticleFuture virology2023

CpG 684: an effective adjuvant for the inactivated COVID-19 vaccine in mice.

Jiandong Liu, Tianle Cang, Congli Jiang, Kelei Li, Siyuan Liu, Haixin Wang, Meirong Wang, Yan Chen, Yan Shao, Jiankai Liu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiandong LiuBeijing Minhai Biotechnology Co. Ltd, Beijing, 102600, China.
Tianle CangBeijing Minhai Biotechnology Co. Ltd, Beijing, 102600, China.
Congli JiangShenzhen Kangtai Biological Products Co., Ltd, Guangzhou, Shenzhen, 518000, China.
Kelei LiBeijing Minhai Biotechnology Co. Ltd, Beijing, 102600, China.
Siyuan LiuBeijing Minhai Biotechnology Co. Ltd, Beijing, 102600, China.
Haixin WangBeijing Minhai Biotechnology Co. Ltd, Beijing, 102600, China.
Meirong WangBeijing Minhai Biotechnology Co. Ltd, Beijing, 102600, China.
Yan ChenJiangsu Taipuriu Biotechnology Co., Ltd, Taizhou Pharmaceutical City, Jiangsu, 225300, China.
Yan ShaoJiangsu Taipuriu Biotechnology Co., Ltd, Taizhou Pharmaceutical City, Jiangsu, 225300, China.
Jiankai LiuBeijing Minhai Biotechnology Co. Ltd, Beijing, 102600, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: This study used CpG 684 as adjuvant of inactivated COVID-19 vaccine to detect a humoral and cellular immune response in mice. Materials & methods: We used 10 and 20 µg CpG 684 as adjuvants of an inactivated COVID-19 vaccine to immunize mice. IgG, IgG1, IgG2a, IgG2b and IgM binding antibodies were detected in serum by ELISA. The IFN-γ cytokine was detected by ELISPOT. Results: CpG 684 improved spike-specific IgG and IgM subtype binding antibodies and increased the neutralizing antibody titer against prototype, Delta and Beta strains. CpG 684 also improved cellular immune response. Conclusion: CpG 684 is an effective adjuvant for inactivated COVID-19 vaccine.

Indexed as

CpGneutralizing antibodySARS-COV-2vaccinevariants

Identifiers

PMID38051998
PMCPMC10241461
OpenAlexW4378980793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.